Top Section/Ad
Top Section/Ad
Most recent
Calendar quirk could keep issuance going in December
◆ Praemia refis at a tighter coupon ◆ Schneider lands tight at the short end ◆ Minimal concessions needed
French biotech seeks to accelerate cancer vaccine program
◆ Single digit premiums offered ◆ Reverse Yankees dominating euro supply ◆ Floaters proving popular with multi-tranche issuers
More articles/Ad
More articles/Ad
More articles
-
Antengene Corp, a clinical stage biopharmaceutical company, is set to launch the roadshow for its Hong Kong IPO next week after wrapping up pre-deal investor education, according to a source close to the listing. -
The Dutch arm of Air France-KLM staved off what looked like certain collapse this week, with the company negotiating a deal with a pilot’s union to put a vital €3.4bn government bailout back on course.
-
Zambia is headed for a default next week, as GlobalCapital understands the bondholder committee responsible for 40% of the sovereign Eurobonds will reject the deferral request in a vote next week.
-
Carlos ‘Sonny’ Dominguez, finance minister of the Philippines, has been forced to swap long-term planning for emergency responses to the coronavirus. He talks to GlobalCapital about what comes next.
-
Gland Pharma, a subsidiary of Shanghai Fosun Pharmaceutical Group, has set the final terms for its Rp64.8bn ($866.5m) IPO in India.
-
Chinese biopharmaceutical firm RemeGen has raised HK$3.99bn ($514.7m) after pricing its IPO at the top of the marketed range, according to a source familiar with the matter.
